• Zydus launches Revahale revefenacin inhalation solution for the treatment of COPD in India

  Zydus Lifesciences has announced the launch of its Revahale revefenacin inhalation solution in India. The company highlights that Revahale is the country’s first once-daily nubulized LAMA for the treatment of COPD, noting that the inhalation… [Read more . . .]

• ReCode Therapeutics names Heather Clark as its new CEO

  ReCode Therapeutics, which is developing inhaled mRNA therapies, announced that Heather Clark will succeed Shehnaaz Suliman as the company’s CEO, with Suliman becoming executive chair of the board. Clark joined ReCode in 2022 and has… [Read more . . .]

• Harrow acquires Tyrvaya varenicline nasal spray for the treatment of dry eye disease

  US-based opthalmic pharmaceuticals company Harrow announced that it will pay Viatris $30 million up front and up to $70 million in milestone payments to acquire Tyrvaya varenicline nasal spray. Tyrvaya was approved by the FDA… [Read more . . .]

• Savara gets 2 new patents covering Molbreevi molgramostim inhalation solution

  Savara has announced that the European Patent Office and the Australian Patent Office have issued new patents covering Molbreevi molgramostim inhalation solution. Both the European patent, No.4121000, and the Australian patent, No. 62/990,810, protect Molbreevi… [Read more . . .]

• MannKind says that the Phase 1b INFLO-1 trial of its nintedanib DPI met its primary endpoint

  MannKind Corporation announced that the Phase 1b INFLO-1 safety and tolerability trial of its nintedanib dry powder inhaler met its primary endpoint, demonstrating safety and tolerability. The multiple ascending dose study enrolled 27 patients with… [Read more . . .]

• Nasus Pharma names Brendan O’Grady as its new CEO

• Chiesi returns the rights to seralutinib DPI for pulmonary hypertension to Gossamer

• Revagenix initiates Phase 1 trial of Rev-56 inhaled antibiotic for NCFB

• FDA approves Cipla’s ANDA for a generic of Advair Diskus fluticasone / salmeterol DPI

• CHMP adopts negative opinion regarding Cessatech and Proveca’s KemSu (CT001) sufentanil / ketamine nasal spray for pediatric patients

More news . . .